A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
The Singapore Institute for Clinical Sciences—a division of the Agency for Science, Technology and Research (A*STAR)—needed to capture data on symptoms of subclinical mood disturbances, with the goal of identifying digital biomarkers of depressive and anxious feelings.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.
Medical device company, Mi-Helper, Inc., needed to find participants with a specific type of migraine. This required a long run-in period and mitigation to reduce the risk of drop-off before participants reached active treatment. In addition, Mi-Helper needed to ensure participants used the at-home device properly.